No­var­tis' sec­ond at­tempt to repli­cate a stun­ning can­cer re­sult falls flat

No­var­tis’ hopes of turn­ing one of the most sur­pris­ing tri­al da­ta points of the last decade in­to a lung can­cer drug has tak­en an­oth­er set­back.

The Swiss phar­ma an­nounced Mon­day that its IL-1 in­hibitor canakinum­ab did not sig­nif­i­cant­ly ex­tend the lives or slow the dis­ease pro­gres­sion of pa­tients with pre­vi­ous­ly un­treat­ed lo­cal­ly ad­vanced or metasta­t­ic non-small cell lung can­cer when com­pared to stan­dard of-care alone.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER